This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
coronavirus disease | 89 |
nervous system | 72 |
multiple sclerosis | 61 |
neurological symptoms | 61 |
novel coronavirus | 60 |
respiratory syndrome | 57 |
acute respiratory | 50 |
ischemic stroke | 49 |
anticancer therapy | 46 |
neurological manifestations | 46 |
icu admission | 44 |
intensive care | 43 |
ms patients | 43 |
severe covid | 43 |
severe acute | 42 |
neurol doi | 39 |
cord uid | 39 |
doc id | 39 |
risk factors | 38 |
acute stroke | 37 |
central nervous | 35 |
neurologic manifestations | 34 |
older patients | 32 |
creative commons | 32 |
syndrome associated | 31 |
neurological diseases | 31 |
respiratory failure | 31 |
two patients | 29 |
stroke care | 29 |
systematic review | 29 |
mental status | 28 |
syndrome coronavirus | 28 |
cerebrospinal fluid | 28 |
general population | 28 |
performance status | 28 |
altered mental | 27 |
neurological complications | 27 |
cerebrovascular disease | 27 |
hospitalized patients | 27 |
informed consent | 27 |
patients admitted | 26 |
case report | 25 |
mechanical ventilation | 25 |
clinical characteristics | 25 |
supplementary material | 25 |
intellectual content | 24 |
commons licence | 24 |
care unit | 23 |
icu discharge | 21 |
pd patients | 21 |
one patient | 21 |
respiratory symptoms | 21 |
clinical course | 21 |
mental health | 21 |
clinical features | 20 |
epidural abscess | 20 |
spinal epidural | 20 |
pa level | 20 |
immune response | 20 |
critically ill | 19 |
cognitive impairment | 19 |
increased risk | 19 |
confirmed covid | 19 |
acute necrotizing | 18 |
viral infection | 18 |
physical activities | 18 |
risk factor | 18 |
case series | 18 |
nasopharyngeal swab | 18 |
first case | 18 |
neuroinvasive potential | 17 |
patients without | 16 |
major role | 16 |
physical activity | 16 |
hemorrhagic ios | 16 |
neurological disorders | 16 |
ischemic ios | 16 |
mortality rate | 16 |
world health | 15 |
cell count | 15 |
health organization | 15 |
peripheral nervous | 15 |
cytokine storm | 15 |
severe infection | 15 |
acute ischemic | 15 |
acute cerebrovascular | 15 |
included studies | 15 |
critical illness | 15 |
neuropsychiatric symptoms | 14 |
reactive protein | 14 |
ill patients | 14 |
review board | 14 |
magnetic resonance | 14 |
patients aged | 14 |
neurological disease | 14 |
icu stay | 14 |
brain mri | 14 |
ethical standards | 14 |
arterial hypertension | 14 |
intravenous thrombolysis | 14 |
laboratory findings | 14 |
mg dl | 14 |
karnofsky performance | 14 |
among patients | 14 |
necrotizing encephalopathy | 14 |
institutional review | 13 |
respiratory distress | 13 |
intensity pa | 13 |
cohort study | 13 |
east respiratory | 13 |
open access | 13 |
reversible encephalopathy | 13 |
reperfusion therapy | 13 |
apache ii | 13 |
stroke patients | 13 |
middle east | 13 |
case reports | 13 |
lyme disease | 13 |
pa levels | 12 |
patients treated | 12 |
old man | 12 |
data collection | 12 |
multicenter study | 12 |
patients affected | 12 |
neurological comorbidities | 12 |
multicenter cohort | 12 |
clinical presentation | 12 |
emergency department | 12 |
logistic regression | 12 |
april th | 12 |
resonance imaging | 12 |
posterior reversible | 12 |
ct scan | 12 |
patients infected | 12 |
five patients | 11 |
csf igg | 11 |
electronic supplementary | 11 |
authors declare | 11 |
patients may | 11 |
online version | 11 |
coronavirus infection | 11 |
controlled trial | 11 |
written informed | 11 |
neuromuscular disease | 11 |
independently associated | 11 |
mean age | 11 |
poor outcome | 11 |
oligoclonal bands | 11 |
may th | 11 |
elderly patients | 11 |
stroke center | 11 |
hospital death | 11 |
neuroimaging studies | 11 |
significant difference | 11 |
three patients | 11 |
suspected stroke | 11 |
patients presenting | 11 |
igg bands | 11 |
authorized users | 11 |
median age | 11 |
author contributions | 11 |
contains supplementary | 11 |
health care | 11 |
hospital discharge | 11 |
amyloid status | 11 |
intracerebral hemorrhage | 10 |
converting enzyme | 10 |
corresponding author | 10 |
clinical parameters | 10 |
may play | 10 |
endothelial cells | 10 |
six patients | 10 |
intensity physical | 10 |
chronic subdural | 10 |
white matter | 10 |
encephalopathy syndrome | 10 |
consecutive patients | 10 |
barre syndrome | 10 |
higher risk | 10 |
miller fisher | 9 |
ischaemic stroke | 9 |
energy expenditure | 9 |
patients suffering | 9 |
healthy subjects | 9 |
daily life | 9 |
disease course | 9 |
severity outcomes | 9 |
systematic reviews | 9 |
depression scale | 9 |
movement disorders | 9 |
skeletal muscle | 9 |
spinal cord | 9 |
upsit score | 9 |
oligoclonal igg | 9 |
neurological examination | 9 |
computed tomography | 9 |
total pa | 9 |
associated acute | 9 |
observational study | 9 |
continuous variables | 9 |
large vessel | 9 |
discharged alive | 9 |
brain barrier | 9 |
specific antibodies | 9 |
categorical variables | 9 |
head injury | 9 |
past history | 9 |
cerebrovascular diseases | 9 |
mri findings | 9 |
polyneuritis cranialis | 9 |
cov may | 9 |
vascular risk | 9 |
four patients | 9 |
facial diplegia | 9 |
ethics approval | 8 |
newly diagnosed | 8 |
encephalitis associated | 8 |
older people | 8 |
intraarterial thrombectomy | 8 |
intended use | 8 |
large cohort | 8 |
white blood | 8 |
ethical approval | 8 |
psychiatric symptomatology | 8 |
cardiovascular risk | 8 |
herpes simplex | 8 |
brain ct | 8 |
acute motor | 8 |
fisher syndrome | 8 |
appropriate credit | 8 |
cov infection | 8 |
cardiovascular surgery | 8 |
permission directly | 8 |
atrial fibrillation | 8 |
severe sars | 8 |
renal failure | 8 |
national health | 8 |
without ios | 8 |
credit line | 8 |
party material | 8 |
neuromyelitis optica | 8 |
commons attribution | 8 |
social distancing | 8 |
older adults | 8 |
give appropriate | 8 |
human coronaviruses | 8 |
third party | 8 |
copyright holder | 8 |
retrospective case | 8 |
csf samples | 8 |
permits use | 8 |
statutory regulation | 8 |
demyelinating lesions | 8 |
system involvement | 8 |
sars coronavirus | 8 |
control period | 8 |
unless indicated | 8 |
infection severity | 8 |
psychological well | 8 |
original author | 8 |
corona virus | 8 |
financial conflicts | 8 |
public health | 8 |
disease duration | 8 |
clinical symptoms | 8 |
neuropsychiatric manifestations | 8 |
lower extremities | 8 |
older age | 8 |
international license | 8 |
neuromuscular diseases | 8 |
mild cognitive | 8 |
ad patients | 8 |
two cases | 8 |
mvpa level | 8 |
will need | 8 |
medical history | 8 |
study protocol | 8 |
visit http | 8 |
permitted use | 8 |
factors associated | 8 |
neurologic complications | 8 |
meningitis encephalitis | 8 |
retrospective study | 8 |
obtain permission | 8 |
indicated otherwise | 8 |
disease severity | 8 |
vessel stroke | 8 |
years old | 8 |
may also | 7 |
blood cell | 7 |
borrelia burgdorferi | 7 |
endovascular treatment | 7 |
clinical trials | 7 |
ace receptors | 7 |
giovanni xxiii | 7 |
significant differences | 7 |
future neurodegeneration | 7 |
grade glioma | 7 |
creat iveco | 7 |
papa giovanni | 7 |
iveco mmons | 7 |
preferred reporting | 7 |
year survival | 7 |
subdural haematoma | 7 |
respondents reported | 7 |
potential risk | 7 |
hemorrhagic necrotizing | 7 |
old woman | 7 |
status epilepticus | 7 |
brain tissue | 7 |
acute hemorrhagic | 7 |
covid impact | 7 |
posterior circulation | 7 |
clinical practice | 7 |
significant reduction | 7 |
severe disease | 7 |
health commission | 7 |
cortical thickness | 7 |
days later | 7 |
mri showed | 7 |
large artery | 7 |
common neurological | 7 |
direct viral | 7 |
pns involvement | 7 |
patients presented | 7 |
social isolation | 7 |
respiratory tract | 7 |
multiple organ | 7 |
year mortality | 7 |
evidence suggests | 7 |
olfactory identification | 7 |
care units | 7 |
inflammatory response | 7 |
distress syndrome | 7 |
licen ses | 7 |
organ failure | 7 |
onset stroke | 7 |
entorhinal cortex | 7 |
prognostic factors | 7 |
analysis showed | 7 |
patients developed | 7 |
depressive symptoms | 7 |
current study | 7 |
neurological signs | 7 |
cardiovascular disease | 7 |
clinical data | 7 |
impaired consciousness | 7 |
sedative agents | 7 |
ms symptomatology | 7 |
subdural hematoma | 7 |
burgdorferi antigen | 7 |
possible association | 7 |
pooled analysis | 7 |
csf analysis | 7 |
specific igg | 7 |
reporting items | 7 |
viral infections | 7 |
neurological presentation | 7 |
org licen | 7 |
severe patients | 6 |
blood cells | 6 |
author states | 6 |
patients underwent | 6 |
human coronavirus | 6 |
vein thrombosis | 6 |
diagnostic criteria | 6 |
carotid artery | 6 |
hospital anxiety | 6 |
clinical picture | 6 |
study period | 6 |
hgg patients | 6 |
study group | 6 |
present study | 6 |
higher mortality | 6 |
related stroke | 6 |
tested positive | 6 |
gustatory dysfunction | 6 |
focal neurological | 6 |
one case | 6 |
biogen idec | 6 |
possible explanation | 6 |
potential role | 6 |
severe course | 6 |
statistical analyses | 6 |
sclerosis patients | 6 |
cortex thickness | 6 |
motor neuron | 6 |
following covid | 6 |
impaired walking | 6 |
lower limbs | 6 |
lockdown orders | 6 |
new york | 6 |
neurological deficits | 6 |
optica spectrum | 6 |
existing neurological | 6 |
aneurysmal subarachnoid | 6 |
medical records | 6 |
mortality rates | 6 |
csf testing | 6 |
comprehensive stroke | 6 |
north america | 6 |
brain injury | 6 |
developed stroke | 6 |
time period | 6 |
healthy controls | 6 |
patients discharged | 6 |
presenting feature | 6 |
asst papa | 6 |
respiratory system | 6 |
cancer patients | 6 |
well known | 6 |
sample size | 6 |
polymerase chain | 6 |
cns demyelinating | 6 |
ii score | 6 |
emergency room | 6 |
traumatic brain | 6 |
transverse myelitis | 6 |
neurological comorbidity | 6 |
demyelinating disease | 6 |
stroke symptoms | 6 |
neurologic features | 6 |
chain reaction | 6 |
nine patients | 6 |
patients hospitalized | 6 |
efficacy agents | 6 |
march th | 6 |
treatment times | 6 |
manifestations associated | 6 |
weighted imaging | 6 |
cancer progression | 6 |
malignant brain | 6 |
subarachnoid haemorrhage | 6 |
control study | 6 |
life expectancy | 6 |
diabetes mellitus | 6 |
patient received | 6 |
primary malignant | 6 |
tendon reflexes | 6 |
term outcome | 6 |
antigen specificity | 6 |
necrotizing myelitis | 6 |
pupillary changes | 6 |
exclusion criteria | 5 |
neuroimmunological diseases | 5 |
prothrombin time | 5 |
adult patients | 5 |
au ml | 5 |
funding provided | 5 |
transient ischemic | 5 |
northern italy | 5 |
seven patients | 5 |
walking activity | 5 |
upper respiratory | 5 |
high number | 5 |
glasgow coma | 5 |
inflammatory demyelinating | 5 |
peripheral nerves | 5 |
access funding | 5 |
clinical trial | 5 |
clinical findings | 5 |
retrospective multicenter | 5 |
stroke recognition | 5 |
birth cohort | 5 |
severe cases | 5 |
neurologic involvement | 5 |
initial presentation | 5 |
high mortality | 5 |
literature search | 5 |
olfactory bulb | 5 |
acquired pneumonia | 5 |
lupus anticoagulant | 5 |
cytokine release | 5 |
early detection | 5 |
survival rate | 5 |
neuronal death | 5 |
functional outcome | 5 |
antibody response | 5 |
related quality | 5 |
normal range | 5 |
commission guidelines | 5 |
organ infection | 5 |
hospital stroke | 5 |
di torino | 5 |
study guillain | 5 |
imaging findings | 5 |
total igg | 5 |
pharyngeal swab | 5 |
unstable vital | 5 |
nasopharyngeal swabs | 5 |
adapted version | 5 |
total weekly | 5 |
typical clinical | 5 |
positive csf | 5 |
within days | 5 |
significantly higher | 5 |
clinical management | 5 |
acute subdural | 5 |
conservative treatment | 5 |
medical center | 5 |
many patients | 5 |
studies included | 5 |
lumbar puncture | 5 |
median time | 5 |
exact test | 5 |
multivariate logistic | 5 |
autoimmune encephalitis | 5 |
brain tumors | 5 |
coronavirus pneumonia | 5 |
pathophysiologic mechanisms | 5 |
ms disease | 5 |
ad signature | 5 |
acute flaccid | 5 |
patients showed | 5 |
antiphospholipid antibodies | 5 |
five cases | 5 |
human ace | 5 |
preclinical ad | 5 |
february rd | 5 |
standards laid | 5 |
pulmonary disease | 5 |
mri features | 5 |
impact interview | 5 |
plasma exchange | 5 |
cerebral artery | 5 |
severe clinical | 5 |
contributed equally | 5 |
axonal neuropathy | 5 |
two time | 5 |
subarachnoid hemorrhage | 5 |
oxygen saturation | 5 |
nationwide analysis | 5 |
discharged home | 5 |
neurological involvement | 5 |
supplementary table | 5 |
data analysis | 5 |
tract infection | 5 |
four cases | 5 |
clinical spectrum | 5 |
neurodegenerative diseases | 5 |
regression analysis | 5 |
time periods | 5 |
defining severity | 5 |
clinical outcomes | 5 |
brain tissues | 5 |
ethics committee | 5 |
mice transgenic | 5 |
signature cortical | 5 |
research council | 5 |
covid infection | 5 |
imaging markers | 5 |
motor symptoms | 5 |
muscle mass | 5 |
two periods | 5 |
decompressive craniectomy | 5 |
united states | 5 |
patient data | 5 |
viral particles | 5 |
progressive multiple | 5 |
neurological complication | 5 |
without dementia | 5 |
clinical manifestations | 5 |
increased vulnerability | 5 |
developed respiratory | 5 |
authors contributed | 5 |
rapidly spread | 5 |
multivariable analysis | 5 |
steroid treatment | 5 |
zika virus | 5 |
symptoms including | 5 |
stroke associated | 5 |
respiratory rate | 5 |
multivariate analysis | 5 |
interstitial pneumonia | 5 |
vital signs | 5 |
antiganglioside antibodies | 5 |
cns infection | 5 |
hemorrhagic stroke | 5 |
neuromuscular disorders | 5 |
neoplastic diseases | 5 |
retrospective cohort | 5 |
ms dmts | 5 |
molecular mimicry | 5 |
endothelial cell | 5 |
modifying therapies | 5 |
randomised controlled | 5 |
infectious disease | 5 |
gbs cases | 5 |
included patients | 5 |
weekly pa | 5 |
major criteria | 5 |
nasal obstruction | 5 |
vessel occlusion | 5 |
studies reported | 5 |
nerve palsy | 4 |
specific antibody | 4 |
studies showed | 4 |
bilateral peripheral | 4 |
myocardial infarction | 4 |
least one | 4 |
weighted images | 4 |
clinical deterioration | 4 |
primary sea | 4 |
two conditions | 4 |
severe form | 4 |
occasional cluster | 4 |
first step | 4 |
protective role | 4 |
critical care | 4 |
examination showed | 4 |
patients diagnosed | 4 |
aneurysm trial | 4 |
dimer levels | 4 |
excess non | 4 |
lymphocytic pleocytosis | 4 |
processing speed | 4 |
olfactory nerves | 4 |
discontinuing dmts | 4 |
survey instrument | 4 |
endovascular coiling | 4 |
groin puncture | 4 |
interquartile range | 4 |
underlying neurological | 4 |
varicella zoster | 4 |
infectious diseases | 4 |
physical inactivity | 4 |
peripheral neuropathy | 4 |
smell identification | 4 |
via telephone | 4 |
disseminated encephalomyelitis | 4 |
higher rates | 4 |
muscle injury | 4 |
muscle strength | 4 |
cerebral venous | 4 |
animal models | 4 |
room air | 4 |
patients received | 4 |
quantitative data | 4 |
csf sars | 4 |
negative consequences | 4 |
significantly lower | 4 |
blood pressure | 4 |
extracorporeal membrane | 4 |
previous studies | 4 |
physical exercise | 4 |
nmd showed | 4 |
among neurological | 4 |
acute disseminated | 4 |
without assistance | 4 |
mechanical thrombectomy | 4 |
elevated inflammatory | 4 |
often leads | 4 |
stroke presentations | 4 |
lymphocytic meningoradiculitis | 4 |
necrotizing hemorrhagic | 4 |
cognitive decline | 4 |
aneurysmal sah | 4 |
solid cancer | 4 |
therapeutic options | 4 |
hospital admissions | 4 |
shorter time | 4 |
pandemic outbreak | 4 |
neurologic syndrome | 4 |
rehabilitation facility | 4 |
collected data | 4 |
guillain barre | 4 |
olfactory nerve | 4 |
time intervals | 4 |
clinical improvement | 4 |
study showed | 4 |
baseline characteristics | 4 |
higher scores | 4 |
health survey | 4 |
inversion recovery | 4 |
search strategy | 4 |
observational cohort | 4 |
neuromuscular junction | 4 |
occlusive treatment | 4 |
chest ct | 4 |
prothrombotic state | 4 |
square test | 4 |
patients reported | 4 |
necrotizing encephalitis | 4 |
cns involvement | 4 |
confusional states | 4 |
causes neuronal | 4 |
stroke treatment | 4 |
form health | 4 |
ischemic attack | 4 |
autoimmune diseases | 4 |
common neurotropic | 4 |
infections may | 4 |
daily number | 4 |
patient care | 4 |
practice guideline | 4 |
tissue damage | 4 |
amsterdam area | 4 |
laboratory tests | 4 |
neurological conditions | 4 |
acute inflammatory | 4 |
high risk | 4 |
clinical recovery | 4 |
severe forms | 4 |
particularly vulnerable | 4 |
distribution pattern | 4 |
tumefactive demyelinating | 4 |
covid deaths | 4 |
protein levels | 4 |
identification test | 4 |
minor criteria | 4 |
taken together | 4 |
rating scale | 4 |
humoral immune | 4 |
muscle weakness | 4 |
observational studies | 4 |
infection causes | 4 |
dry cough | 4 |
interest dr | 4 |
mt remained | 4 |
peripheral facial | 4 |
invasive ventilation | 4 |
recently published | 4 |
facial nerve | 4 |
left middle | 4 |
publication bias | 4 |
symptoms may | 4 |
time interval | 4 |
intracranial hemorrhage | 4 |
eight patients | 4 |
european study | 4 |
data available | 4 |
severe ards | 4 |
nitrocellulose filters | 4 |
intrathecally produced | 4 |
national institute | 4 |
tested negative | 4 |
intravenous immunoglobulin | 4 |
national survey | 4 |
situation report | 4 |
myasthenia gravis | 4 |
severity based | 4 |
even though | 4 |
coronavirus oc | 4 |
systemic inflammatory | 4 |
aged years | 4 |
acute physiology | 4 |
data synthesis | 4 |
neurological impairment | 4 |
overall rate | 4 |
persistent secretion | 4 |
mrc national | 4 |
identification deficits | 4 |
tissue distribution | 4 |
nd patients | 4 |
clinical severity | 4 |
per month | 4 |
poorer oi | 4 |
newly developed | 4 |
showed reduced | 4 |
two factors | 4 |
severe respiratory | 4 |
bilateral facial | 4 |
demographic data | 4 |
infected pneumonia | 4 |
ischemic strokes | 4 |
cell infection | 4 |
patients undergoing | 4 |
pa intensity | 4 |
sars cov | 4 |
findings suggest | 4 |
laminar cortical | 4 |
walking activities | 4 |
missing data | 4 |
age group | 4 |
confidence interval | 4 |
patients died | 4 |
wuhan clinical | 4 |
findings revealed | 4 |
ms society | 4 |
funding none | 4 |
symptom onset | 4 |
stroke admissions | 4 |
immune system | 4 |
endothelial dysfunction | 4 |
protein level | 4 |
published literature | 4 |
cognitively normal | 4 |
deep tendon | 4 |
symptoms associated | 4 |
nerve conduction | 4 |
poor condition | 4 |
demyelinating polyradiculoneuropathy | 4 |
performed using | 4 |
pyogenic infection | 4 |
ii scores | 4 |
middle cerebral | 4 |
mild respiratory | 4 |
cognitive rehabilitation | 4 |
viral entry | 4 |
substantial proportion | 4 |
hospital delays | 4 |
study procedures | 4 |
hemorrhagic encephalopathy | 4 |
individual patient | 4 |
first one | 4 |
remained stable | 4 |
surgical treatment | 4 |
future studies | 4 |
motor axonal | 4 |
care workers | 4 |
acute symptomatic | 4 |
different neurological | 4 |
disease control | 4 |
responsive encephalitis | 4 |
following descriptive | 4 |
innate immune | 4 |
gustatory dysfunctions | 4 |
parent rct | 4 |
probable cas | 4 |
common etiology | 4 |
study included | 4 |
simplex virus | 4 |
patient populations | 4 |
coma scale | 4 |
frontal lobe | 4 |
neuroimmunological disorders | 4 |
artery dissection | 4 |
univariate analysis | 4 |
ms dmt | 4 |
matter hyperintensity | 4 |
muscular injury | 4 |
participating hospitals | 4 |
submitted work | 4 |
two months | 4 |
asan medical | 4 |
early recognition | 4 |
based case | 4 |
travel grants | 4 |
facial weakness | 4 |
frailty index | 4 |
epidural space | 4 |
antibody responses | 4 |
slightly increased | 4 |
fatality rate | 4 |
membrane oxygenation | 4 |
recent retrospective | 4 |
new cases | 4 |
reported neurological | 3 |
lung cancer | 3 |
igg titre | 3 |
digital revolution | 3 |
without respiratory | 3 |
likely due | 3 |
effects model | 3 |
oi impairment | 3 |
csf protein | 3 |
outcome measures | 3 |
improve outcomes | 3 |
csf studies | 3 |
icu treatment | 3 |
territory involvement | 3 |
intravenous drug | 3 |
storm syndromes | 3 |
syndrome following | 3 |
lactate dehydrogenase | 3 |
spinal invasion | 3 |
clinical condition | 3 |
speaker honoraria | 3 |
mild strokes | 3 |
german multicenter | 3 |
current literature | 3 |
odor identification | 3 |
high doses | 3 |
uncertain reasons | 3 |
continuous upsit | 3 |
possible cause | 3 |
indirect involvement | 3 |
replacement therapy | 3 |
manifestations include | 3 |
mumps meningitis | 3 |
significant proportion | 3 |
severe outcome | 3 |
emergency departments | 3 |
per se | 3 |
liver failure | 3 |
text articles | 3 |
high morbidity | 3 |
infection risk | 3 |
nasal cavity | 3 |
patient completely | 3 |
acute phase | 3 |
deep vein | 3 |
useful information | 3 |
ms specialists | 3 |
spine mri | 3 |
dmt prescribing | 3 |
release syndrome | 3 |
vessel disease | 3 |
cerebral hemorrhage | 3 |
study heterogeneity | 3 |
lyon stroke | 3 |
zoster virus | 3 |
system disorders | 3 |
three days | 3 |
term consequences | 3 |
completely recovered | 3 |
brain tumor | 3 |
upper extremities | 3 |
medical research | 3 |
higher bmi | 3 |
may induce | 3 |
stroke network | 3 |
first symptoms | 3 |
chronic illness | 3 |
versus survival | 3 |
multivariable logistic | 3 |
identified articles | 3 |
subcortical white | 3 |
cases month | 3 |
accumulating evidence | 3 |
three cases | 3 |
ab anti | 3 |
protein peak | 3 |
anxiety depression | 3 |
mrc scale | 3 |
older population | 3 |
patients clinical | 3 |
high risks | 3 |
glioma discharged | 3 |
descriptive terms | 3 |
three hospitals | 3 |
regional network | 3 |
chronic meningoradiculitis | 3 |
hematologic malignancy | 3 |
circulation infarctions | 3 |
substantia nigra | 3 |
urgently needed | 3 |
vascular comorbidities | 3 |
developed acute | 3 |
identify factors | 3 |
respiratory disease | 3 |
prior months | 3 |
sex differences | 3 |
viral shedding | 3 |
bed rest | 3 |
ruptured aneurysms | 3 |
impact survey | 3 |
full sample | 3 |
absolute numbers | 3 |
new coronavirus | 3 |
following surgery | 3 |
spectrum disorder | 3 |
international guidelines | 3 |
diagnosed cancer | 3 |
descriptive study | 3 |
neurological patients | 3 |
impact scale | 3 |
remains unclear | 3 |
british birth | 3 |
develop neurological | 3 |
antiviral agents | 3 |
infectious agents | 3 |
demographic characteristics | 3 |
may result | 3 |
expression profiling | 3 |
sclerosis impact | 3 |
moderate forms | 3 |
acute onset | 3 |
positive serum | 3 |
bilateral carotid | 3 |
ganglioside antibodies | 3 |
developing covid | 3 |
remains speculative | 3 |
crucial role | 3 |
male patients | 3 |
following days | 3 |
recent systematic | 3 |
inflammatory biomarkers | 3 |
flaccid myelitis | 3 |
home infusions | 3 |
viral replication | 3 |
without neurological | 3 |
immune responses | 3 |
certain dmts | 3 |
conduction studies | 3 |
oxford centre | 3 |
barrier breakdown | 3 |
study team | 3 |
symptoms related | 3 |
sectional survey | 3 |
infection might | 3 |
artery ischaemic | 3 |
antiplatelet agents | 3 |
early surgery | 3 |
rapid spread | 3 |
revascularization procedures | 3 |
cancer diagnosis | 3 |
brain lesions | 3 |
italian covid | 3 |
diffusion coefficient | 3 |
cd antibody | 3 |
increasing number | 3 |
treatment options | 3 |
hemorrhagic transformation | 3 |
vascular endothelium | 3 |
stroke regional | 3 |
mri scan | 3 |
higher rate | 3 |
claustrum sign | 3 |
diluted csf | 3 |
parkinson disease | 3 |
retrospective observational | 3 |
overlapping patient | 3 |
prescribing patterns | 3 |
qualified investigator | 3 |
activity questionnaire | 3 |
address neurological | 3 |
factors based | 3 |
neurological manifestation | 3 |
table shows | 3 |
statistical significance | 3 |
one month | 3 |
acquired covid | 3 |
negative impact | 3 |
mass loss | 3 |
angiotensin system | 3 |
normal white | 3 |
thromboembolic complications | 3 |
moderate covid | 3 |
chronic obstructive | 3 |
never presented | 3 |
comorbid conditions | 3 |
vasogenic edema | 3 |
clinical manifestation | 3 |
observational analysis | 3 |
produced igg | 3 |
several potential | 3 |
research support | 3 |
functional status | 3 |
respiratory function | 3 |
initial stage | 3 |
icu mortality | 3 |
consider cytokine | 3 |
functional receptor | 3 |
early guillain | 3 |
important intellectual | 3 |
min wk | 3 |
still hospitalized | 3 |
drug abuser | 3 |
demographic values | 3 |
cognitive function | 3 |
higher prevalence | 3 |
hyperintensity volume | 3 |
marked reduction | 3 |
contracting covid | 3 |
patients included | 3 |
high proportion | 3 |
clinical evidence | 3 |
radicular pain | 3 |
series study | 3 |
covid excess | 3 |
subarachnoid aneurysm | 3 |
patients suffered | 3 |
also found | 3 |
multicenter data | 3 |
random effects | 3 |
syndrome due | 3 |
encephalomyelitis virus | 3 |
presenting symptom | 3 |
time delays | 3 |
sea development | 3 |
obstructive pulmonary | 3 |
funnel plot | 3 |
ace protein | 3 |
radiologic findings | 3 |
high incidence | 3 |
time prolongation | 3 |
contrast enhancement | 3 |
research priorities | 3 |
study reports | 3 |
haemorrhagic stroke | 3 |
specific neurological | 3 |
hippocampal volumes | 3 |
perceived impact | 3 |
herpes virus | 3 |
immunoblot technique | 3 |
linear regression | 3 |
italian population | 3 |
instrumental tests | 3 |
hyperacute stroke | 3 |
also important | 3 |
confidence intervals | 3 |
lombardy region | 3 |
critical patients | 3 |
lower rate | 3 |
studies defining | 3 |
adult inpatients | 3 |
covid patients | 3 |
smell dysfunction | 3 |
showed evidence | 3 |
bj contributed | 3 |
pennsylvania smell | 3 |
nile virus | 3 |
one study | 3 |
based study | 3 |
provide acute | 3 |
three studies | 3 |
neurosurgical patients | 3 |
multicenter european | 3 |
th level | 3 |
virus may | 3 |
international physical | 3 |
patients date | 3 |
puncture time | 3 |
poisson regression | 3 |
primary stroke | 3 |
people living | 3 |
previously discussed | 3 |
study design | 3 |
highest number | 3 |
virus infections | 3 |
greater risk | 3 |
lung injury | 3 |
literature review | 3 |
patients present | 3 |
common infectious | 3 |
performance quality | 3 |
severity outcome | 3 |
international subarachnoid | 3 |
including stroke | 3 |
neuronal retrograde | 3 |
causal relationship | 3 |
electronic databases | 3 |
stroke management | 3 |
hypercoagulable state | 3 |
otherwise healthy | 3 |
intracranial aneurysms | 3 |
mediated neurological | 3 |
intrathecal synthesis | 3 |
point increase | 3 |
resulted positive | 3 |
neuromuscular clinic | 3 |
age rather | 3 |
death versus | 3 |
study reported | 3 |
creatine kinase | 3 |
china neurologic | 3 |
gbs related | 3 |
various neuropsychiatric | 3 |
sensitivity analyses | 3 |
rate observed | 3 |
may increase | 3 |
grade iii | 3 |
later amendments | 3 |
two days | 3 |
test results | 3 |
pathophysiological mechanisms | 3 |
health evaluation | 3 |
randomized controlled | 3 |
della salute | 3 |
prolong viral | 3 |
stroke incidence | 3 |
worth noting | 3 |
haemorrhagic strokes | 3 |
dmts may | 3 |
poor outcomes | 3 |
cranial nerve | 3 |
retrospective analysis | 3 |
hematologic malignancies | 3 |
might also | 3 |
neurology department | 3 |
previously published | 3 |
level parameter | 3 |
three categories | 3 |
weight heparin | 3 |
cardioembolic stroke | 3 |
patients gave | 3 |
cerebral vein | 3 |
wuhan china | 3 |
intracranial cytokine | 3 |
novel virus | 3 |
control periods | 3 |
critical revision | 3 |
fluid analysis | 3 |
participants reported | 3 |
west nile | 3 |
seven days | 3 |
associated guillain | 3 |
demyelinating polyneuropathy | 3 |
old complication | 3 |
pcr testing | 3 |
asymptomatic bacterial | 3 |
della scienza | 3 |
report data | 3 |
potential explanations | 3 |
advisory board | 3 |
serologic tests | 3 |
abscess spinal | 3 |
stroke manifestation | 3 |
pulmonary infarction | 3 |
human neural | 3 |
detailed description | 3 |
dopamine neurons | 3 |
basic science | 3 |
significant decrease | 3 |
age ranging | 3 |
frequent comorbidity | 3 |
infection rate | 3 |
antineuronal antibodies | 3 |
virus infection | 3 |
hospital mortality | 3 |
also associated | 3 |
italian series | 3 |
respiratory support | 3 |
icu survivors | 3 |
cause mortality | 3 |
full text | 3 |
csf examination | 3 |
will discuss | 3 |
invasive surgery | 3 |
projekt deal | 3 |
rate year | 3 |
official clinical | 3 |
medical advice | 3 |
ms population | 3 |
affected patients | 3 |
modified frailty | 3 |
acknowledgements open | 3 |
week follow | 3 |
deidentified data | 3 |
pandemic may | 3 |
spinal mri | 3 |
neurologic symptoms | 3 |
sclerosis treated | 3 |
quality assessment | 3 |
french intensive | 3 |
expert group | 3 |
small vessel | 3 |
nerve involvement | 3 |
disseminated intravascular | 3 |
stroke occurred | 3 |
lvo stroke | 3 |
case definition | 3 |
brain health | 3 |
syndrome guillain | 3 |
patients self | 3 |
prospective cohort | 3 |
olfactory function | 3 |
swallowing assessment | 3 |
spatial disorientation | 3 |
ace receptor | 3 |
csf antibodies | 3 |
initial conservative | 3 |
scottish government | 3 |
neurotropic virus | 3 |
psychological impact | 3 |
available regarding | 3 |
persistent infection | 3 |
month period | 3 |
cell depletion | 3 |
conduction velocity | 3 |
thrombolytic therapy | 3 |
disease progression | 3 |
possible cas | 3 |
neurological sequalae | 3 |
higher efficacy | 3 |
distancing measures | 3 |
system infection | 3 |
viral encephalitis | 3 |
randomised trial | 3 |
evident infective | 3 |
reports grants | 3 |
apparent diffusion | 3 |
intrathecal production | 3 |
scoping review | 3 |
confirmed diagnosis | 3 |
instrumental evaluations | 3 |
recent study | 3 |
based medicine | 3 |
peripheral blood | 3 |
hippocampal volume | 3 |
inhospital death | 3 |
longitudinal studies | 3 |
study aimed | 3 |
significant positive | 3 |
week periods | 3 |
alzheimer disease | 3 |
oropharyngeal swab | 3 |
spectrum disorders | 3 |
neurological syndrome | 3 |
claustrum lesions | 3 |
showed lower | 3 |
several limitations | 3 |
disease activity | 3 |
ruptured aneurysm | 3 |
medical icu | 3 |
reported outcomes | 3 |
sinus thrombosis | 3 |
hospital rehabilitation | 3 |
little change | 3 |
deceased patients | 3 |
patient age | 3 |
available evidence | 3 |
remaining patients | 3 |
chinese cohorts | 3 |
care society | 3 |
illness neuropathy | 3 |
respiratory illness | 3 |
suspected covid | 3 |
existing cerebrovascular | 3 |
upper limbs | 3 |
specific oligoclonal | 3 |
university hospital | 3 |
united kingdom | 3 |
progressive weakness | 3 |
visual inspection | 3 |
previous years | 3 |
ethical standard | 3 |
health component | 3 |
progressive course | 3 |
may occur | 3 |
brain scans | 3 |
american academy | 3 |
unmet needs | 3 |
italian programme | 3 |
respiratory manifestations | 3 |
human respiratory | 3 |
authors report | 3 |
radiological findings | 3 |
cns symptoms | 3 |
final version | 3 |
illness myopathy | 3 |
new infection | 3 |
weeks later | 3 |
jc virus | 3 |
quality indicators | 3 |
sore throat | 3 |
comorbidities including | 3 |
infection develops | 3 |
binary logistic | 3 |
infective source | 3 |
different pathogenesis | 3 |
gi symptoms | 3 |
assessed using | 3 |
lower efficacy | 3 |
average number | 3 |
study brain | 2 |
acknowledgments open | 2 |
cohort profile | 2 |
pooled data | 2 |
tested patients | 2 |
stich i | 2 |
measures adopted | 2 |
zur wiesch | 2 |
subdural hematomas | 2 |
laboratory testing | 2 |
neurological syndromes | 2 |
failure due | 2 |
hiv patients | 2 |
claustral neurons | 2 |
isoelectric focusing | 2 |
patient diagnosed | 2 |
cardiovascular conditions | 2 |
higher survival | 2 |
sars pathogenesis | 2 |
similar clusters | 2 |
point likert | 2 |
sample contamination | 2 |
related functional | 2 |
agents following | 2 |
dosing interval | 2 |
date available | 2 |
internal carotid | 2 |
outstanding questions | 2 |
walk independently | 2 |
causal association | 2 |
poor prognosis | 2 |
research consortia | 2 |
psychological distress | 2 |
linear mixed | 2 |
repeat spinal | 2 |
radiological manifestations | 2 |
infection key | 2 |
atypical variant | 2 |
burgdorferi specific | 2 |
small ground | 2 |
respiratory coronaviruses | 2 |
data concerning | 2 |
bilateral leg | 2 |
systemic circulation | 2 |
national research | 2 |
olfactory loss | 2 |
hyperintense signal | 2 |
renal function | 2 |
mortality year | 2 |
met pre | 2 |
academic research | 2 |
efficacy dmts | 2 |
stroke registries | 2 |
supporting features | 2 |
normal individuals | 2 |
excluded patients | 2 |
parenchyma sample | 2 |
muscle atrophy | 2 |
early ct | 2 |
evaluation since | 2 |
cardiorespiratory center | 2 |
american thoracic | 2 |
provide informed | 2 |
two groups | 2 |
previously reported | 2 |
human participants | 2 |
intravenous alteplase | 2 |
coronavirus causes | 2 |
individual multicenter | 2 |
stroke unit | 2 |
difference resulted | 2 |
neurologists worldwide | 2 |
model selection | 2 |
mild neurological | 2 |
authors read | 2 |
significant increase | 2 |
negatively influenced | 2 |
different populations | 2 |
care delivery | 2 |
electron microscopy | 2 |
becoming infected | 2 |
action underlying | 2 |
ecass ii | 2 |
patient date | 2 |
neurosurgical unit | 2 |
gustatory disorders | 2 |
skeleton muscle | 2 |
sedimentation rate | 2 |
day shows | 2 |
thrombotic microangiopathy | 2 |
motor demyelinating | 2 |
extensive tissue | 2 |
lower pcs | 2 |
independent reviewers | 2 |
studies assessing | 2 |
stroke compared | 2 |
questions related | 2 |
extensive overview | 2 |
single center | 2 |
offers clinicians | 2 |
case fatality | 2 |
pcr technique | 2 |
vertebral artery | 2 |
increased stress | 2 |
symptomatic seizures | 2 |
pandemic impact | 2 |
international mission | 2 |
american version | 2 |
term effects | 2 |
confirmed acute | 2 |
prominent agitation | 2 |
mean difference | 2 |
current covid | 2 |
resection specimen | 2 |
arterial thromboembolic | 2 |
three washing | 2 |
study concept | 2 |
spinal surgery | 2 |
editorial board | 2 |
neurologic events | 2 |
data support | 2 |
include anosmia | 2 |
ventilation may | 2 |
cognitive dysfunction | 2 |
perform regular | 2 |
venous sinus | 2 |
consistency among | 2 |
remitting multiple | 2 |
relatively high | 2 |
adequate therapeutic | 2 |
systemic infections | 2 |
patients guillain | 2 |
study aims | 2 |
may predispose | 2 |
renal replacement | 2 |
walking ability | 2 |
robust evidence | 2 |
competing interests | 2 |
committee london | 2 |
pressure fluctuations | 2 |
sea patients | 2 |
reperfusion procedures | 2 |
common cold | 2 |
er admittance | 2 |
among medicare | 2 |
increased protein | 2 |
multifocal laminar | 2 |
including altered | 2 |
previous clinical | 2 |
severe strokes | 2 |
rabbit anti | 2 |
systemic signs | 2 |
disease onset | 2 |
receives research | 2 |
highest variability | 2 |
infection signs | 2 |
studies published | 2 |
invasive procedures | 2 |
subjects without | 2 |
total intracranial | 2 |
protein mg | 2 |
questions assessing | 2 |
relevant upper | 2 |
csdh recurrence | 2 |
speed ability | 2 |
amyloid deposition | 2 |
similar findings | 2 |
scienza di | 2 |
pre covid | 2 |
spontaneous supratentorial | 2 |
clinical depression | 2 |
thrombocytopenic purpura | 2 |
sum test | 2 |
medical treatments | 2 |
classified severity | 2 |
pneumonia diagnosis | 2 |
revealed elevated | 2 |
pulmonary embolism | 2 |
continue anticancer | 2 |
risks among | 2 |
study populations | 2 |
research group | 2 |
dichotomized outcome | 2 |
systemic inflammation | 2 |
right lateral | 2 |
demyelinating patterns | 2 |
revised definition | 2 |
emergency services | 2 |
previous year | 2 |
total patients | 2 |
high level | 2 |
two weeks | 2 |
predisposing factors | 2 |
sudden change | 2 |
versus female | 2 |
potential late | 2 |
significance level | 2 |
new diagnoses | 2 |
moderate severe | 2 |
chemoattractant protein | 2 |
improved within | 2 |
ray showed | 2 |
ahmed idbaih | 2 |
cutaneous plantar | 2 |
normal elderly | 2 |
upsit scores | 2 |
suboptimal sensitivity | 2 |
concomitant risk | 2 |
vast majority | 2 |
determined using | 2 |
canadian neurologists | 2 |
stroke pathway | 2 |
studies extracted | 2 |
infection risks | 2 |
multiple comorbidities | 2 |
sars patients | 2 |
organ systems | 2 |
beck depression | 2 |
sagittal flair | 2 |
dementia care | 2 |
data availability | 2 |
zoster meningoencephalitis | 2 |
host immune | 2 |
underwent recent | 2 |
dehydrogenase levels | 2 |
cytological dissociation | 2 |
reverse transcription | 2 |
swallowing dysfunction | 2 |
patients required | 2 |
severe manifestation | 2 |
patient presented | 2 |
symptoms due | 2 |
especially acute | 2 |
full recovery | 2 |
regression test | 2 |
intravascular coagulation | 2 |
report guillain | 2 |
among people | 2 |
mild fever | 2 |
oc infection | 2 |
cortical subcortical | 2 |
oligoclonal csf | 2 |
additionally reported | 2 |
disease rating | 2 |
male versus | 2 |
hazard ratios | 2 |
patients contracting | 2 |
blue triangles | 2 |
diffusion mri | 2 |
solved discrepancies | 2 |
manifestations occurred | 2 |
units day | 2 |
clinical research | 2 |
also indicate | 2 |
modified version | 2 |
independent risk | 2 |
infect humans | 2 |
relatively unusual | 2 |
physical well | 2 |
antithrombotic agents | 2 |
traumatic stress | 2 |
standard care | 2 |
ich score | 2 |
minor stroke | 2 |
protective vaccine | 2 |
papers published | 2 |
bilateral occipital | 2 |
full access | 2 |
pharmaceutical industries | 2 |
depression symptoms | 2 |
artery disease | 2 |
corresponding immunoblot | 2 |
kind gift | 2 |
potential immunologic | 2 |
moderately increased | 2 |
positive nasopharyngeal | 2 |
stable although | 2 |
modifying therapy | 2 |
igg concentration | 2 |
neurological intensive | 2 |
respondents came | 2 |
april period | 2 |
cerebrovascular accident | 2 |
predictive value | 2 |
oculomotor nerve | 2 |
critical review | 2 |
brain computerized | 2 |
bayesian model | 2 |
strongly associated | 2 |
improved outcomes | 2 |
cognitive deficits | 2 |
chest radiography | 2 |
transcription polymerase | 2 |
neurological deterioration | 2 |
sclerosis society | 2 |
brain parenchyma | 2 |
severity subsuming | 2 |
erythrocyte sedimentation | 2 |
icu cluster | 2 |
different severity | 2 |
cortical areas | 2 |
term neurological | 2 |
average age | 2 |
main results | 2 |
especially olfactory | 2 |
cas fulfilled | 2 |
specific alterations | 2 |
tests revealed | 2 |
significant changes | 2 |
prevention measures | 2 |
late onset | 2 |
paucisymptomatic infections | 2 |
medication use | 2 |
di stefano | 2 |
prisma guidelines | 2 |
studies suggest | 2 |
move towards | 2 |
coronavirus testing | 2 |
equal definitions | 2 |
received honoraria | 2 |
right mca | 2 |
march st | 2 |
lower motor | 2 |
cells causing | 2 |
patients typically | 2 |
early diagnosis | 2 |
spss version | 2 |
cortical damage | 2 |
diagnostic tests | 2 |
three years | 2 |
depression scores | 2 |
developed ios | 2 |
bed icu | 2 |
st april | 2 |
sea incidence | 2 |
present case | 2 |
clinicians useful | 2 |
mixed central | 2 |
peripheral polyneuropathies | 2 |
older person | 2 |
significant correlations | 2 |
presumptive case | 2 |
likert scale | 2 |
proper managements | 2 |
first presumptive | 2 |
infection guillain | 2 |
paper drafting | 2 |
intracranial volume | 2 |
good condition | 2 |
descriptive observational | 2 |
proposed neurotropic | 2 |
venous thrombosis | 2 |
motor weakness | 2 |
reported covid | 2 |
simplified acute | 2 |
demyelinating neuropathy | 2 |
demographic factors | 2 |
previously administered | 2 |
patients remains | 2 |
nerve sonography | 2 |
streptococcus pneumoniae | 2 |
cohort studies | 2 |
national institutes | 2 |
presented neurologic | 2 |
including pcr | 2 |
governmental restrictions | 2 |
harmonised research | 2 |
age dependent | 2 |
review key | 2 |
long term | 2 |
severity requires | 2 |
main outcome | 2 |
tau pathology | 2 |
china coronavirus | 2 |
charlson comorbidity | 2 |
main analysis | 2 |
lymphocyte counts | 2 |
assessing interventions | 2 |
ift titres | 2 |
rare variant | 2 |
brain samples | 2 |
lower risk | 2 |
plantar reflex | 2 |
neurological findings | 2 |
available biomarkers | 2 |
associated neurological | 2 |
highly congruent | 2 |
autopsy samples | 2 |
mild lymphocytic | 2 |
great opportunity | 2 |
patients complained | 2 |
spine showed | 2 |
important risk | 2 |
cell counts | 2 |
several mechanisms | 2 |
neurological diagnoses | 2 |
syndrome related | 2 |
widespread covid | 2 |
named sars | 2 |
particular interest | 2 |
glycoprotein antibodies | 2 |
showed bilateral | 2 |
mycoplasma pneumoniae | 2 |
showed elevated | 2 |
sectional study | 2 |
health systems | 2 |
disease patients | 2 |
invasive mechanical | 2 |
main reasons | 2 |
two potential | 2 |
viral diseases | 2 |
patient population | 2 |
viral nucleic | 2 |
older ms | 2 |
science research | 2 |
cerebral circulation | 2 |
initially presented | 2 |
patients displayed | 2 |
reported risk | 2 |
coronavirus responsible | 2 |
bmi variables | 2 |
neuron disorder | 2 |
barr virus | 2 |
widely used | 2 |
term follow | 2 |
confirmed cas | 2 |
status including | 2 |
three participating | 2 |
terms relating | 2 |
neuroimmune diseases | 2 |
community sample | 2 |
sum tests | 2 |
less frequent | 2 |
amyloid fibrils | 2 |
possible atypical | 2 |
financial impact | 2 |
vascular pathology | 2 |
candidate variables | 2 |
barrow ruptured | 2 |
review articles | 2 |
ethics service | 2 |
organizing pneumonia | 2 |
include fever | 2 |
clinical outcome | 2 |
enough evidence | 2 |
antiviral therapy | 2 |
maria title | 2 |
physical health | 2 |
spastic paraparesis | 2 |
mortality compared | 2 |
idh mutation | 2 |
repeated csf | 2 |
consecutive series | 2 |
multiple choice | 2 |
significantly different | 2 |
perivascular cuff | 2 |
flair hyperintense | 2 |
infectious causes | 2 |
albuminocytologic dissociation | 2 |
man diagnosed | 2 |
prognostic comorbidity | 2 |
ten days | 2 |
care agreement | 2 |
final manuscript | 2 |
associated stroke | 2 |
spinal fluid | 2 |
hemorrhagic strokes | 2 |
normal time | 2 |
free text | 2 |
breached blood | 2 |
secondary use | 2 |
likely secondary | 2 |
including ms | 2 |
center study | 2 |
magnifying glass | 2 |
tertiary hospital | 2 |
neurological diagnosis | 2 |
comparator period | 2 |
meier survival | 2 |
calculated according | 2 |
stroke stroke | 2 |
pa reduction | 2 |
deidentified clinical | 2 |
especially neuropsychiatric | 2 |
qp rrwr | 2 |
traumatic head | 2 |
regular exercise | 2 |
admission observed | 2 |
neurodegenerative versus | 2 |
poorly understood | 2 |
reported cases | 2 |
selection process | 2 |
several cases | 2 |
studi di | 2 |
day fully | 2 |
medicine rating | 2 |
study outcomes | 2 |
elevated protein | 2 |
metabolic encephalopathy | 2 |
good outcomes | 2 |
perfusion imaging | 2 |
also cause | 2 |
risk profile | 2 |
anonymized data | 2 |
specific sars | 2 |
odds ratio | 2 |
considerable impairment | 2 |
total protein | 2 |
chiesi farmaceutici | 2 |
acute myelitis | 2 |
viral genome | 2 |
previous three | 2 |
potential association | 2 |
response rate | 2 |
foramen ovale | 2 |
swine flu | 2 |
showed increased | 2 |
wearing masks | 2 |
irritation signs | 2 |
abnormal coagulation | 2 |
leading causes | 2 |
also reviewed | 2 |
stroke onset | 2 |
cell clones | 2 |
inflammatory cytokine | 2 |
patient developed | 2 |
lockdown follow | 2 |
oligodendrocyte glycoprotein | 2 |
new onset | 2 |
heart disease | 2 |
encephalitis new | 2 |
rare complication | 2 |
symptoms among | 2 |
extensive transverse | 2 |
future development | 2 |
clinical symptom | 2 |
much lower | 2 |
related coronavirus | 2 |
asst pg | 2 |
anticoagulant therapy | 2 |
relevant clinical | 2 |
lumbar spine | 2 |
cooperative acute | 2 |
acute cardiovascular | 2 |
conditions associated | 2 |
retrograde dissemination | 2 |
contagion prevention | 2 |
diagnostic testing | 2 |
emerging spectrum | 2 |
smaller studies | 2 |
paper conception | 2 |
weak bands | 2 |
human experimentation | 2 |
sea occurred | 2 |
pandemic impacted | 2 |
infection affects | 2 |
elevated levels | 2 |
several months | 2 |
compound muscle | 2 |
participants included | 2 |
complication associated | 2 |
neurological illness | 2 |
icu patients | 2 |
patients studied | 2 |
primary brain | 2 |
mimic covid | 2 |
genetic similarity | 2 |
immunologic mechanisms | 2 |
decisions concerning | 2 |
provided approval | 2 |
patient prognosis | 2 |
possible central | 2 |
vitro models | 2 |
two reviewers | 2 |
systematic search | 2 |
european cooperative | 2 |
rare neurological | 2 |
mostly focused | 2 |
canadian respondents | 2 |
involvement compared | 2 |
pao fio | 2 |
underwent surgery | 2 |
manifestations including | 2 |
differently distributed | 2 |
immunocompromised state | 2 |
neurological critical | 2 |
light reflexes | 2 |
health behaviors | 2 |
lean european | 2 |
new pulmonary | 2 |
response syndrome | 2 |
neurosurgical treatment | 2 |
negative sars | 2 |
composite severity | 2 |
lower lobe | 2 |
coronaviruses cause | 2 |
pneumonia associated | 2 |
findings confirmed | 2 |
global burden | 2 |
frequently reported | 2 |
red circles | 2 |
clipping versus | 2 |
cerebrovascular events | 2 |
sudden onset | 2 |
bias towards | 2 |
chronic health | 2 |
report suggests | 2 |
close coordination | 2 |
statistically significant | 2 |
may contribute | 2 |
publicly available | 2 |
odour identification | 2 |
viral invasion | 2 |
depression inventory | 2 |
oligoclonal total | 2 |
healthcare system | 2 |
cognitively impaired | 2 |
mr images | 2 |
neuron disease | 2 |
synthesized within | 2 |
assessment score | 2 |
previously healthy | 2 |
symptoms progressed | 2 |
bilateral pneumonic | 2 |
related targets | 2 |
pneumonic infiltrates | 2 |
clinical information | 2 |
patients experienced | 2 |
inferior part | 2 |
rxv batt | 2 |
unusually high | 2 |
one prior | 2 |
male gender | 2 |
spike binds | 2 |
remain regarding | 2 |
reference lo | 2 |
action potential | 2 |
adaptive immune | 2 |
tapered gradually | 2 |
general electric | 2 |
crp mg | 2 |
epidural abscesses | 2 |
delayed distal | 2 |
poor neurology | 2 |
two investigators | 2 |
radiological interstitial | 2 |
bacterial infections | 2 |
um ntvi | 2 |
common clinical | 2 |
igm igg | 2 |
bacterial superinfection | 2 |
evaluation ii | 2 |
evaluated using | 2 |
staphylococcus aureus | 2 |
patient expressed | 2 |
another one | 2 |
warrants additional | 2 |
muscle rigidity | 2 |
legislative decree | 2 |
including headache | 2 |
study confirms | 2 |
status year | 2 |
twice daily | 2 |
complications associated | 2 |
neurotropic mechanisms | 2 |
authors listed | 2 |
ischemic lesions | 2 |
neurologists believed | 2 |
key performance | 2 |
cjb daps | 2 |
cytokine profile | 2 |
treatment expert | 2 |
csf parameters | 2 |
blood brain | 2 |
identify cases | 2 |
single case | 2 |
college station | 2 |
manifestations otherwise | 2 |
cranial dissection | 2 |
complications related | 2 |
prospective studies | 2 |
main characteristics | 2 |
maria pia | 2 |
related organ | 2 |
cochrane library | 2 |
mitigation strategies | 2 |
vasomotor reactivity | 2 |
term prognosis | 2 |
databases promoting | 2 |
conducted using | 2 |
direct infection | 2 |
human herpes | 2 |
young female | 2 |
lower rates | 2 |
brain regions | 2 |
rna expression | 2 |
published data | 2 |
remote monitoring | 2 |
pay attention | 2 |
comparatively low | 2 |
type respiratory | 2 |
ifn response | 2 |
findings indicate | 2 |
detailed data | 2 |
health stroke | 2 |
surgery versus | 2 |
healthcare resources | 2 |
clinical pattern | 2 |
vice versa | 2 |
inflammatory markers | 2 |
surgical treatments | 2 |
outcome subsuming | 2 |
showed mild | 2 |
distal upper | 2 |
hads depression | 2 |
limited data | 2 |
may represent | 2 |
eligibility criteria | 2 |
university college | 2 |
patient improved | 2 |
developed bladder | 2 |
cord syndrome | 2 |
strongest association | 2 |
delayed diagnosis | 2 |
pn patients | 2 |
unplanned medical | 2 |
study confirmed | 2 |
cranial nerves | 2 |
increases risk | 2 |
low quality | 2 |
develops neurological | 2 |
thrombotic medications | 2 |
stroke scale | 2 |
cerebrovascular insults | 2 |
previous medical | 2 |
neurological sequelae | 2 |
igg anti | 2 |
society institutional | 2 |
serology testing | 2 |
nigrostriatal dopamine | 2 |
physician respondents | 2 |
probnp ng | 2 |
intravenous immune | 2 |
approach covid | 2 |
wherever possible | 2 |
axial ct | 2 |
disease symptomatology | 2 |
increased life | 2 |
pneumonia outbreak | 2 |
recent findings | 2 |
sensory level | 2 |
imaging studies | 2 |
may trigger | 2 |
skeletal muscles | 2 |
compared using | 2 |
primary prevention | 2 |
italian subjects | 2 |
sufficient enough | 2 |
th percentile | 2 |
effect factor | 2 |
excess death | 2 |
corticosteroid therapy | 2 |
component score | 2 |
envelope protein | 2 |
treatment modalities | 2 |
require informed | 2 |
following day | 2 |
including ischemic | 2 |
retrospective design | 2 |
endovascular thrombectomy | 2 |
infanta leonor | 2 |
total daily | 2 |
flair images | 2 |
dipeptidyl peptidase | 2 |
diffuse degenerative | 2 |
may manifest | 2 |
back pain | 2 |
causing anosmia | 2 |
microcirculatory function | 2 |
functional outcomes | 2 |
signal changes | 2 |
cortical brain | 2 |
required intensive | 2 |
specific outcomes | 2 |
elevated csf | 2 |
intracerebral haemorrhage | 2 |
analysis clinical | 2 |
schulze zur | 2 |
outcome compared | 2 |
electroencephalographic confirmation | 2 |
first weeks | 2 |
ms patient | 2 |
advisory boards | 2 |
one week | 2 |
reliable predictor | 2 |
versus initial | 2 |
disease due | 2 |
severity according | 2 |
longer term | 2 |
retrograde spinal | 2 |
four percent | 2 |
mri finding | 2 |
positive reverse | 2 |
regional stroke | 2 |
acetylsalicylic acid | 2 |
chronic stage | 2 |
serious infections | 2 |
worse outcomes | 2 |
therapeutic strategies | 2 |
depression cut | 2 |
study olfactory | 2 |
clearly demonstrated | 2 |
systematically performed | 2 |
natural killer | 2 |
mg twice | 2 |
without nasal | 2 |
incomplete evaluation | 2 |
grade iv | 2 |
final model | 2 |
pd neuropathology | 2 |
stroke beds | 2 |
gian luigi | 2 |
received compensation | 2 |
presented case | 2 |
limbic encephalitis | 2 |
multivariate binary | 2 |
numerous studies | 2 |
weekly level | 2 |
health research | 2 |
immune reaction | 2 |
personal fees | 2 |
received ivig | 2 |
radiological confirmed | 2 |
therapy prior | 2 |
binary amyloid | 2 |
october st | 2 |
normal cutaneous | 2 |
mr imaging | 2 |
elevation myocardial | 2 |
conservative management | 2 |
additional studies | 2 |
axial flair | 2 |
stroke may | 2 |
three groups | 2 |
british version | 2 |
late complication | 2 |
lockdown period | 2 |
new patient | 2 |
subcutaneous enoxaparine | 2 |
active covid | 2 |
five csf | 2 |
relatively small | 2 |
never developed | 2 |
ms clinics | 2 |
papers related | 2 |
acute transverse | 2 |
patients compared | 2 |
pandemic period | 2 |
viral anosmia | 2 |
finally included | 2 |
growing body | 2 |
negative rt | 2 |
completely asymptomatic | 2 |
study coronavirus | 2 |
virus targeting | 2 |
term implications | 2 |
correspondent spinal | 2 |
related encephalopathy | 2 |
icu non | 2 |
chinese clinical | 2 |
national ms | 2 |
corticospinal tract | 2 |
viewpoint review | 2 |
studies conducted | 2 |
neuropsychiatric complications | 2 |
pcr confirmed | 2 |
two nasopharyngeal | 2 |
retrograde synaptic | 2 |
prospective data | 2 |
wilcoxon rank | 2 |
clinical patterns | 2 |
inflammatory reaction | 2 |
cause multiple | 2 |
two databases | 2 |
acute encephalopathy | 2 |
recently reported | 2 |
takes responsibility | 2 |
academic hospital | 2 |
complete resolution | 2 |
olfactory deficits | 2 |
may aid | 2 |
questions remain | 2 |
without systemic | 2 |
additional evidence | 2 |
excessive immune | 2 |
received grant | 2 |
first week | 2 |
unremarkable including | 2 |
ct scans | 2 |
tumefactive demyelination | 2 |
potential neurotropism | 2 |
natural history | 2 |
host defense | 2 |
common carotid | 2 |
stroke services | 2 |
response patterns | 2 |
viral screening | 2 |
emergency medical | 2 |
syndrome key | 2 |
pooled analyses | 2 |
ct angiography | 2 |
overall qol | 2 |
missing values | 2 |
london hospital | 2 |
tingling sensation | 2 |
injectable therapies | 2 |
eo ityc | 2 |
upper motor | 2 |
especially large | 2 |
ad pathology | 2 |
intravenous immunoglobulins | 2 |
infectious etiology | 2 |
scan demonstrated | 2 |
observer agreement | 2 |
olfactory disorders | 2 |
intraarterial thrombi | 2 |
laboratory investigations | 2 |
nursing home | 2 |
outcome data | 2 |
time reverse | 2 |
dmts altogether | 2 |
compromised covid | 2 |
viral disease | 2 |
initial stroke | 2 |
among nmd | 2 |
month follow | 2 |
might represent | 2 |
unfavourable outcome | 2 |
neurologic complication | 2 |
well documented | 2 |
italian multiple | 2 |
also negative | 2 |
pulmonary edema | 2 |
muscle damage | 2 |
randomized clinical | 2 |
associate editor | 2 |
systematic screening | 2 |
i dh | 2 |
standard statement | 2 |
hospital complications | 2 |
psychiatric symptoms | 2 |
fragile patients | 2 |
special role | 2 |
tuberculous meningitis | 2 |
laboratory abnormalities | 2 |
short period | 2 |
firm conclusions | 2 |
recently described | 2 |
will also | 2 |
physiology score | 2 |
score indicates | 2 |
wallis test | 2 |
text evaluation | 2 |
cox proportional | 2 |
earliest phases | 2 |
good outcome | 2 |
system manifestations | 2 |
molecular testing | 2 |
risk profiles | 2 |
performed according | 2 |
authors thank | 2 |
symptomatic covid | 2 |
classifying prognostic | 2 |
wuhan cohort | 2 |
fio ratio | 2 |
higher score | 2 |
health disparities | 2 |
patients due | 2 |
medicare beneficiaries | 2 |
existing chronic | 2 |
level difference | 2 |
princiotta cariddi | 2 |
proximity marker | 2 |
workflow parameters | 2 |
infective agents | 2 |
week period | 2 |
autoimmune epilepsy | 2 |
china clinical | 2 |
population ever | 2 |
information regarding | 2 |
disease clinical | 2 |
patients across | 2 |
intrathecal virus | 2 |
survival probability | 2 |
flaccid paralysis | 2 |
approved may | 2 |
acute covid | 2 |
geriatric assessment | 2 |
collected verbally | 2 |
thoracic society | 2 |
infection prevention | 2 |
commonly reported | 2 |
muscle action | 2 |
therapy planned | 2 |
indicates greater | 2 |
accelerating aging | 2 |
colleagues reported | 2 |
key role | 2 |
red blood | 2 |
also appears | 2 |
among studies | 2 |
endothelial damage | 2 |
several case | 2 |
significant relationships | 2 |
case notification | 2 |
infection may | 2 |
financial interest | 2 |
transgenic mice | 2 |
young people | 2 |
consider starting | 2 |
investigate whether | 2 |
stroke study | 2 |
herpetic encephalitis | 2 |
another coronavirus | 2 |
cell therapies | 2 |
thoracic ct | 2 |
prognostic value | 2 |
term mortality | 2 |
term chronic | 2 |
studies comprising | 2 |
monocyte chemoattractant | 2 |
injury manifestations | 2 |
neural cell | 2 |
therapy rate | 2 |
narrative review | 2 |
csf immunoglobulins | 2 |
selection procedure | 2 |
diffusion reduction | 2 |
similar age | 2 |
neurologic diagnoses | 2 |
psychological states | 2 |
numerous reports | 2 |
one necrotizing | 2 |
syndrome corona | 2 |
neurological ward | 2 |
potential susceptibility | 2 |
parainfectious autoimmune | 2 |
board member | 2 |
coronavirus associated | 2 |
included individuals | 2 |
weekly number | 2 |
neurosurgical clipping | 2 |
times higher | 2 |
comprehensive geriatric | 2 |
electric healthcare | 2 |
increased anxiety | 2 |
minimal change | 2 |
analysis revealed | 2 |
incubation period | 2 |
xxiii provided | 2 |
last search | 2 |
enoxaparine mg | 2 |
organ damage | 2 |
previously mentioned | 2 |
specific neuro | 2 |
reported manifestations | 2 |
brain magnetic | 2 |
coronavirus infections | 2 |
ethical board | 2 |
chronic meningoradiculomyelitis | 2 |
atypical pneumonia | 2 |
significantly associated | 2 |
infectious mechanisms | 2 |
reported patients | 2 |
negative igm | 2 |
treatments including | 2 |
increased morbidity | 2 |
first draft | 2 |
like symptoms | 2 |
neurovirulent agents | 2 |
ottawa scale | 2 |
yet available | 2 |
aetiological agent | 2 |
light touch | 2 |
metagenomic sequencing | 2 |
normal cell | 2 |
negative history | 2 |
pneumonia caused | 2 |
published cases | 2 |
author solved | 2 |
response within | 2 |
mental scale | 2 |
reliably report | 2 |
china large | 2 |
new method | 2 |
negative nasopharyngeal | 2 |
heart rate | 2 |
onset neurological | 2 |
perceived health | 2 |
one single | 2 |
protein synthesis | 2 |
current state | 2 |
scores indicating | 2 |
parietal lobes | 2 |
pet scanning | 2 |
disease following | 2 |
varying patterns | 2 |
college london | 2 |
period compared | 2 |
rituximab since | 2 |
various neurological | 2 |
clinical examination | 2 |
human igg | 2 |
manifestations observed | 2 |
mis compared | 2 |
oral steroid | 2 |
common comorbidity | 2 |
stroke severity | 2 |
risk estimate | 2 |
minutes week | 2 |
urgent need | 2 |
considered instead | 2 |
sea may | 2 |
high expression | 2 |
scientific advisory | 2 |
two independent | 2 |
eli lilly | 2 |
neurosurgical care | 2 |
neuropsychiatric sequelae | 2 |
monoclonal antibody | 2 |
immune thrombocytopenic | 2 |
eye movement | 2 |
stroke epidemiology | 2 |
study also | 2 |
clinically suspected | 2 |
cause endothelial | 2 |
years age | 2 |
mip mkef | 2 |
computerized tomography | 2 |
months later | 2 |
mayo clinic | 2 |
risk may | 2 |
quarantine condition | 2 |
socially isolated | 2 |
coagulation parameters | 2 |
tract signs | 2 |
might worsen | 2 |
symptoms signs | 2 |
elevated creatine | 2 |
study received | 2 |
stranded rna | 2 |
stress disorder | 2 |
study enrollment | 2 |
strategies including | 2 |